832076-92-3

Basic information

• Product Name: 4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE
• Synonyms: 4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE;4-(Chloromethyl)-2-(4-chlorophenyl)-5-;4-(Chloromethyl)-2-(4-chlorophenyl)-5-methyl-1,3-oxazole
• CAS NO: 832076-92-3
• Molecular Formula: C₁₁H₉Cl₂NO
• Molecular Weight: 242.1
• Mol File: 832076-92-3.mol

Chemical Properties

• Melting Point: 90-92 °C
• Boiling Point: 365.2±52.0 °C(Predicted)
• Appearance: /
• Density: 1.297±0.06 g/cm3(Predicted)
• PKA: -0.86±0.26(Predicted)
• CAS DataBase Reference: 4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE(832076-92-3)
• EPA Substance Registry System: 4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE(832076-92-3)

Safety Data

• Hazardous Substances Data: 832076-92-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE is used as a chemical intermediate for the synthesis of bioactive compounds. Its unique structure allows it to be a key component in the creation of new pharmaceuticals, contributing to drug discovery efforts.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE serves as a valuable tool for investigating biological processes. Its properties make it instrumental in understanding and potentially manipulating these processes to develop new therapeutic agents.
Used in Chemical Synthesis:
4-CHLOROMETHYL-2-(4-CHLORO-PHENYL)-5-METHYL-OXAZOLE is also used in chemical synthesis processes, where its reactivity and structural features are leveraged to produce a variety of compounds with potential applications in different industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 832076-74-1 2-(4-chlorophenyl)-4,5-dimethyl-1,3-oxazole 
• 109544-27-6 2-(4-chlorophenyl)-4,5-dimethyl-1,3-oxazole-3-oxide 
• 110828-81-4 2,3-butanedione-2-monoxime 
• 75-36-5 acetyl chloride 

Downstream Products

• 1000998-61-7 methyl 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetate 
• 1000998-64-0 5-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)-2-fluorobenzaldehyde 
• 1000998-68-4 methyl N-(5-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)-2-fluorobenzyl)-N-(methoxycarbonyl)glycinate 
• 897765-44-5 1-((2-(4-chlorolphenyl)-5-methyloxazol-4-yl)methyl)piperidine-4-carboxylic acid 
• 1107661-72-2 2-amino-6-({[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile 
• 1107663-28-4 2-amino-6-({[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}sulphanyl)-4-(4-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl)pyridine-3,5-dicarbonitrile 

Relevant articles and documents

Oxazolyl-Pyrimidines As Antibacterial And Antitubercular Agents: Synthesis, Biological Evaluation, in-silico ADMET And Molecular Docking Study

In search of novel biologically potent compounds, some new oxazolyl pyrimidines (7a-g) have been prepared in the current investigation. All new compounds were characterized using various spectroanalytical techniques such as FT-IR, NMR (1H & 13C), X-Ray single crystal diffractometer, elemental analysis, and mass spectral analysis. Further, the structure of one of the chalcone derivative 6b has been studied by X-Ray single crystal diffractometer. All new hybrids (7a-f) were screened in vitro for their antitubercular activity against M. tuberculosis H37Rv. All the newly prepared molecules exhibited good anti-mycobacterial activity. Amongst all compounds, 7d, 7e and 7f demonstrated the highest potency (MIC = 3.12 μg/mL). In addition, all the new derivatives were also screened for their in vitro antibacterial activity against three selected bacterial strains. New compounds have been docked for the CYP121 enzyme with favorable binding interactions. Further, in silico ADMET prediction and drug-like properties were also evaluated signifying that compounds are encouraging candidates for the design and development of new anti-TB agents with enriched activity and enhanced safety profile.

Synthesis and molecular docking study of new 1,3-oxazole clubbed pyridyl-pyrazolines as anticancer and antimicrobial agents

The present investigation is in the quest of some novel biologically potent heterocyclic compounds 1-aryl-3-(2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl)-propenones 6(a-e) and [5-aryl-3-(2-{(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl)}-4,5-dihydro-1H-pyrazol-1-yl)]-(pyridin-4-yl)methanone 7(a-e) incorporated with biologically active heterocyclic entities namely oxazole, pyrazoline and pyridine. The structures of all the compounds were elucidated using various spectroanalytical techniques such as FT-IR, 1H NMR, 13C NMR and mass spectrometry. The synthesized compounds were studied for their anticancer activity at the National Cancer Institute (NCI, USA) against 60 cancer cell line panel. Data of anticancer activity study revealed that the compound 6(d) has the highest potency. Furthermore, all the compounds were studied for their in vitro antibacterial and antifungal activities. As documented, all the prepared compounds performed well against these pathogenic strains. Moreover, data acquired from the molecular docking studies are very inspiring with respect to the potential utilization of these compounds to help overcome microbe resistance to pharmaceutical drugs.

1,3-Oxazole-isoniazid hybrids: Synthesis, antitubercular activity, and their docking studies

A series of novel N′-([2-aryl-5-methyl-1,3-oxazole-4-yl]methylene)isonicotino/nicotino hydrazides 10a-l were prepared by the condensation reaction of 2-aryl-5-methyl-1,3-oxazole-4-carbaldehydes 8a-f with the corresponding isonicotino/nicotino hydrazides 9

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases

Adenosine is known to be released under a variety of physiological and pathophysiological conditions to facilitate the protection and regeneration of injured ischemic tissues. The activation of myocardial adenosine A1 receptors (A1Rs) has been shown to inhibit myocardial pathologies associated with ischemia and reperfusion injury, suggesting several options for new cardiovascular therapies. When full A1R agonists are used, the desired protective and regenerative cardiovascular effects are usually overshadowed by unintended pharmacological effects such as induction of bradycardia, atrioventricular (AV) blocks, and sedation. These unwanted effects can be overcome by using partial A1R agonists. Starting from previously reported capadenoson we evaluated options to tailor A1R agonists to a specific partiality range, thereby optimizing the therapeutic window. This led to the identification of the potent and selective agonist neladenoson, which shows the desired partial response on the A1R, resulting in cardioprotection without sedative effects or cardiac AV blocks. To circumvent solubility and formulation issues for neladenoson, a prodrug approach was pursued. The dipeptide ester neladenoson bialanate hydrochloride showed significantly improved solubility and exposure after oral administration. Neladenoson bialanate hydrochloride is currently being evaluated in clinical trials for the treatment of heart failure.

Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of 7ii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

FUSED CYANOPYRIDINES AND THE USE THEREOF

The present application relates to novel substituted fused cyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

AMINO ACID ESTER PRODRUGS AND THE USE THEREOF

The present application relates to amino acid ester prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitriles, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE

The present application relates to novel cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF

The present application relates to novel 4-cycloalkyl- and 4-heterocycloalkyl-3,5-dicyano-2-thio-pyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.